A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess ZPL389 efficacy and safety in subjects with moderate to severe atopic dermatitis.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 360 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging Study to Assess the Safety and Efficacy of Multiple Oral ZPL389 Doses in Patients With Moderate to Severe Atopic Dermatitis (ZEST Trial)
Actual Study Start Date: November 14, 2018
Estimated Primary Completion Date: December 18, 2020
Estimated Study Completion Date: January 15, 2021
Arms:
- Placebo Comparator: placebo
- Experimental: ZPL389 Dose 1
- Experimental: ZPL389 Dose 2
- Experimental: ZPL389 Dose 3
- Experimental: ZPL389 Dose 4
| Category | Value |
|---|---|
| Date last updated at source | 2019-10-01 |
| Study type(s) | Interventional |
| Expected enrolment | 360 |
| Study start date | 2018-11-14 |
| Estimated primary completion date | 2020-12-18 |